Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier
Abstract Introduction Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early‐stage subjects do not worsen clinically during a clinical trial, and a neurodegenerative measure predictive of decline...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12325 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142315560697856 |
|---|---|
| author | Dawn C. Matthews Ana S. Lukic Randolph D. Andrews Miles N. Wernick Stephen C. Strother Mark E. Schmidt for the Alzheimer's Disease Neuroimaging Initiative |
| author_facet | Dawn C. Matthews Ana S. Lukic Randolph D. Andrews Miles N. Wernick Stephen C. Strother Mark E. Schmidt for the Alzheimer's Disease Neuroimaging Initiative |
| author_sort | Dawn C. Matthews |
| collection | DOAJ |
| description | Abstract Introduction Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early‐stage subjects do not worsen clinically during a clinical trial, and a neurodegenerative measure predictive of decline could provide critical information. Studies have shown correspondence between perfusion measured by early amyloid frames post‐tracer injection and fluorodeoxyglucose (FDG) positron emission tomography (PET), but with limitations in sensitivity. Multivariate machine learning approaches may offer a more sensitive means for detection of disease related changes as we have demonstrated with FDG. Methods Using summed dynamic florbetapir image frames acquired during the first 6 minutes post‐injection for 107 Alzheimer's Disease Neuroimaging Initiative subjects, we applied optimized machine learning to develop and test image classifiers aimed at measuring AD progression. Early frame amyloid (EFA) classification was compared to that of an independently developed FDG PET AD progression classifier by scoring the FDG scans of the same subjects at the same time point. Score distributions and correlation with clinical endpoints were compared to those obtained from FDG. Region of interest measures were compared between EFA and FDG to further understand discrimination performance. Results The EFA classifier produced a primary pattern similar to that of the FDG classifier whose expression correlated highly with the FDG pattern (R‐squared 0.71), discriminated cognitively normal (NL) amyloid negative (Am–) subjects from all Am+ groups, and that correlated in Am+ subjects with Mini‐Mental State Examination, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Assessment Scale–13‐item Cognitive subscale (R = 0.59, 0.63, 0.73) and with subsequent 24‐month changes in these measures (R = 0.67, 0.73, 0.50). Discussion Our results support the ability to use EFA with a multivariate machine learning–derived classifier to obtain a sensitive measure of AD‐related loss in neuronal function that correlates with FDG PET in preclinical and early prodromal stages as well as in late mild cognitive impairment and dementia. Highlights The summed initial post‐injection minutes of florbetapir positron emission tomography correlate with fluorodeoxyglucose. A machine learning classifier enabled sensitive detection of early prodromal Alzheimer's disease. Early frame amyloid (EFA) classifier scores correlate with subsequent change in Mini‐Mental State Examination, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Assessment Scale–13‐item Cognitive subscale. EFA classifier effect sizes and clinical prediction outperformed region of interest standardized uptake value ratio. EFA classification may aid in stratifying patients to assess treatment effect. |
| format | Article |
| id | doaj-art-fe825d9fea5c446f92ce531936bd978c |
| institution | Kabale University |
| issn | 2352-8737 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-fe825d9fea5c446f92ce531936bd978c2024-12-03T12:37:31ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12325Measurement of neurodegeneration using a multivariate early frame amyloid PET classifierDawn C. Matthews0Ana S. Lukic1Randolph D. Andrews2Miles N. Wernick3Stephen C. Strother4Mark E. Schmidt5for the Alzheimer's Disease Neuroimaging InitiativeADM Diagnostics, Inc. Northbrook Illinois USAADM Diagnostics, Inc. Northbrook Illinois USAADM Diagnostics, Inc. Northbrook Illinois USAADM Diagnostics, Inc. Northbrook Illinois USABaycrest Hospital and Department of Medical Biophysics University of Toronto North York Ontario CanadaJanssen Research and Development Division of Janssen Pharmaceutica Beerse BelgiumAbstract Introduction Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early‐stage subjects do not worsen clinically during a clinical trial, and a neurodegenerative measure predictive of decline could provide critical information. Studies have shown correspondence between perfusion measured by early amyloid frames post‐tracer injection and fluorodeoxyglucose (FDG) positron emission tomography (PET), but with limitations in sensitivity. Multivariate machine learning approaches may offer a more sensitive means for detection of disease related changes as we have demonstrated with FDG. Methods Using summed dynamic florbetapir image frames acquired during the first 6 minutes post‐injection for 107 Alzheimer's Disease Neuroimaging Initiative subjects, we applied optimized machine learning to develop and test image classifiers aimed at measuring AD progression. Early frame amyloid (EFA) classification was compared to that of an independently developed FDG PET AD progression classifier by scoring the FDG scans of the same subjects at the same time point. Score distributions and correlation with clinical endpoints were compared to those obtained from FDG. Region of interest measures were compared between EFA and FDG to further understand discrimination performance. Results The EFA classifier produced a primary pattern similar to that of the FDG classifier whose expression correlated highly with the FDG pattern (R‐squared 0.71), discriminated cognitively normal (NL) amyloid negative (Am–) subjects from all Am+ groups, and that correlated in Am+ subjects with Mini‐Mental State Examination, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Assessment Scale–13‐item Cognitive subscale (R = 0.59, 0.63, 0.73) and with subsequent 24‐month changes in these measures (R = 0.67, 0.73, 0.50). Discussion Our results support the ability to use EFA with a multivariate machine learning–derived classifier to obtain a sensitive measure of AD‐related loss in neuronal function that correlates with FDG PET in preclinical and early prodromal stages as well as in late mild cognitive impairment and dementia. Highlights The summed initial post‐injection minutes of florbetapir positron emission tomography correlate with fluorodeoxyglucose. A machine learning classifier enabled sensitive detection of early prodromal Alzheimer's disease. Early frame amyloid (EFA) classifier scores correlate with subsequent change in Mini‐Mental State Examination, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Assessment Scale–13‐item Cognitive subscale. EFA classifier effect sizes and clinical prediction outperformed region of interest standardized uptake value ratio. EFA classification may aid in stratifying patients to assess treatment effect.https://doi.org/10.1002/trc2.12325Alzheimer's diseaseamyloidearly frame amyloidEFAfluorodeoxyglucosemachine learning |
| spellingShingle | Dawn C. Matthews Ana S. Lukic Randolph D. Andrews Miles N. Wernick Stephen C. Strother Mark E. Schmidt for the Alzheimer's Disease Neuroimaging Initiative Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier Alzheimer’s & Dementia: Translational Research & Clinical Interventions Alzheimer's disease amyloid early frame amyloid EFA fluorodeoxyglucose machine learning |
| title | Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier |
| title_full | Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier |
| title_fullStr | Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier |
| title_full_unstemmed | Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier |
| title_short | Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier |
| title_sort | measurement of neurodegeneration using a multivariate early frame amyloid pet classifier |
| topic | Alzheimer's disease amyloid early frame amyloid EFA fluorodeoxyglucose machine learning |
| url | https://doi.org/10.1002/trc2.12325 |
| work_keys_str_mv | AT dawncmatthews measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier AT anaslukic measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier AT randolphdandrews measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier AT milesnwernick measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier AT stephencstrother measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier AT markeschmidt measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier AT forthealzheimersdiseaseneuroimaginginitiative measurementofneurodegenerationusingamultivariateearlyframeamyloidpetclassifier |